Taiwan · Delayed Price · Currency is TWD CH Biotech R&D Statistics
Total Valuation
CH Biotech R&D has a market cap or net worth of TWD 9.18 billion. The enterprise value is 9.41 billion.
| Market Cap | 9.18B |
| Enterprise Value | 9.41B |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | Sep 1, 2026 |
Share Statistics
CH Biotech R&D has 100.80 million shares outstanding. The number of shares has decreased by -0.26% in one year.
| Current Share Class | 100.80M |
| Shares Outstanding | 100.80M |
| Shares Change (YoY) | -0.26% |
| Shares Change (QoQ) | -1.24% |
| Owned by Insiders (%) | 25.35% |
| Owned by Institutions (%) | 0.03% |
| Float | 31.15M |
Valuation Ratios
The trailing PE ratio is 15.50.
| PE Ratio | 15.50 |
| Forward PE | n/a |
| PS Ratio | 4.90 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 3.51 |
| P/FCF Ratio | 12.39 |
| P/OCF Ratio | 10.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.47, with an EV/FCF ratio of 12.69.
| EV / Earnings | 15.56 |
| EV / Sales | 5.02 |
| EV / EBITDA | 10.47 |
| EV / EBIT | 13.83 |
| EV / FCF | 12.69 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.09 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 0.96 |
| Debt / FCF | 1.17 |
| Interest Coverage | 42.23 |
Financial Efficiency
Return on equity (ROE) is 22.76% and return on invested capital (ROIC) is 20.26%.
| Return on Equity (ROE) | 22.76% |
| Return on Assets (ROA) | 11.17% |
| Return on Invested Capital (ROIC) | 20.26% |
| Return on Capital Employed (ROCE) | 24.33% |
| Weighted Average Cost of Capital (WACC) | 5.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.49 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, CH Biotech R&D has paid 131.66 million in taxes.
| Income Tax | 131.66M |
| Effective Tax Rate | 17.88% |
Stock Price Statistics
The stock price has decreased by -4.21% in the last 52 weeks. The beta is 0.23, so CH Biotech R&D's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -4.21% |
| 50-Day Moving Average | 92.22 |
| 200-Day Moving Average | 91.91 |
| Relative Strength Index (RSI) | 39.72 |
| Average Volume (20 Days) | 126,385 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CH Biotech R&D had revenue of TWD 1.87 billion and earned 604.70 million in profits. Earnings per share was 5.88.
| Revenue | 1.87B |
| Gross Profit | 1.58B |
| Operating Income | 681.83M |
| Pretax Income | 736.30M |
| Net Income | 604.70M |
| EBITDA | 871.10M |
| EBIT | 681.83M |
| Earnings Per Share (EPS) | 5.88 |
Balance Sheet
The company has 643.92 million in cash and 868.36 million in debt, with a net cash position of -224.45 million or -2.23 per share.
| Cash & Cash Equivalents | 643.92M |
| Total Debt | 868.36M |
| Net Cash | -224.45M |
| Net Cash Per Share | -2.23 |
| Equity (Book Value) | 2.63B |
| Book Value Per Share | 26.14 |
| Working Capital | 89.14M |
Cash Flow
In the last 12 months, operating cash flow was 897.01 million and capital expenditures -155.64 million, giving a free cash flow of 741.37 million.
| Operating Cash Flow | 897.01M |
| Capital Expenditures | -155.64M |
| Depreciation & Amortization | 189.27M |
| Net Borrowing | -42.65M |
| Free Cash Flow | 741.37M |
| FCF Per Share | 7.35 |
Margins
Gross margin is 84.14%, with operating and profit margins of 36.38% and 32.27%.
| Gross Margin | 84.14% |
| Operating Margin | 36.38% |
| Pretax Margin | 39.29% |
| Profit Margin | 32.27% |
| EBITDA Margin | 46.48% |
| EBIT Margin | 36.38% |
| FCF Margin | 39.56% |
Dividends & Yields
This stock pays an annual dividend of 4.80, which amounts to a dividend yield of 5.25%.
| Dividend Per Share | 4.80 |
| Dividend Yield | 5.25% |
| Dividend Growth (YoY) | 17.07% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 81.60% |
| Buyback Yield | 0.26% |
| Shareholder Yield | 5.51% |
| Earnings Yield | 6.59% |
| FCF Yield | 8.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2022. It was a forward split with a ratio of 1.15.
| Last Split Date | Jul 26, 2022 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
CH Biotech R&D has an Altman Z-Score of 6.49 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 7 |